P1174: PI3K INHIBITOR LINPERLISIB COMBINED WITH GEMCITABINE AND OXALIPATIN (GEMOX) IN RELAPSED AND/OR REFRACTORY DLBCL: ANALYSIS BASED ON TUMOR BIOLOGY

P1174: PI3K INHIBITOR LINPERLISIB COMBINED WITH GEMCITABINE AND OXALIPATIN (GEMOX) IN RELAPSED AND/OR REFRACTORY DLBCL: ANALYSIS BASED ON TUMOR BIOLOGY

Bibliographic Details
Main Authors:	LI Zhi-Ming, Peng Sun, Hong Cen, Hai-Yan Yang, Rui Huang, Zhen Cai, Xue-Kui Gu
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000971592.88393.d2

Similar Items

PB2272: PI3KΔ INHIBITOR LINPERLISIB FOR PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL
by: Lihua Qiu, et al.
Published: (2023-08-01)

PB2269: PI3KΔ INHIBITOR LINPERLISIB FOR ELDERLY PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: SUBGROUP ANALYSIS OF A PHASE 2 TRIAL
by: Xiuhua Sun, et al.
Published: (2023-08-01)

P1119: THE ORAL PI3KΔ INHIBITOR LINPERLISIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: A SINGLE-ARM MULTICENTER PHASE 2 CLINICAL TRIAL
by: T. wang, et al.
Published: (2022-06-01)

P1695: REAL-WORLD SURVIVAL, HEALTHCARE RESOURCE UTILIZATION, AND COSTS AMONG U.S. ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH R-GEMOX IN THE RELAPSED/REFRACTORY SETTING
by: Mahek Garg, et al.
Published: (2023-08-01)

Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL
by: Zhang J, et al.
Published: (2023-02-01)

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy
by: Vera Rentsch, et al.
Published: (2022-05-01)

Real-World Evidence on Palliative Gemcitabine and Oxaliplatin (GemOx) Combination Chemotherapy in Advanced Biliary Tract Cancer
by: Hanna Lagenfelt, et al.
Published: (2021-07-01)

Extranucleolar CYCLON Staining Pattern Is Strongly Associated to Relapse/Refractory Disease in R-CHOP–treated DLBCL
by: Antonin Bouroumeau, et al.
Published: (2021-07-01)

Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context
by: Abdulhaq H, et al.
Published: (2023-07-01)

Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma
by: Roch Houot, et al.
Published: (2022-02-01)

P1213: SUBCUTANEOUS EPCORITAMAB WITH GEMOX INDUCED HIGH RESPONSE RATES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
by: B. E. Wahlin, et al.
Published: (2022-06-01)

The future of the past: attitudes to conservation 1174-1974 /
by: Fawcett, Jane
Published: (1976)

P1090: CAMRELIZUMAB (CAM) COMBINED WITH GEMOX CHEMOTHERAPY RESULTS IN HIGH COMPLETE METABOLIC RESPONSE RATES IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA (CHL): A PHASE II TRIAL
by: Y. Xie, et al.
Published: (2022-06-01)

P1120: NOVEL TARGETED AGENTS IN COMBINATION WITH R-ICE (R-ICE-X) BASED ON GENOTYPING IN RELAPSED/REFRACTORY DLBCL.
by: Shen Yige, et al.
Published: (2023-08-01)

Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial
by: Yanfei Liu, et al.
Published: (2024-03-01)

Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution
by: Qi Quan, et al.
Published: (2020-12-01)

P1165: BETALUTIN® IN PATIENTS WITH RELAPSED/ REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
by: T. Illidge, et al.
Published: (2022-06-01)

P1168: DURABLE REMISSION AFTER SEQUENTIAL CD19/20 CAR T-CELL “CAKE-ICING” THERAPY OCCURRED IN REFRACTORY/RELAPSED DLBCL
by: Peihao Zheng, et al.
Published: (2023-08-01)

Outcome and toxicity of ifosfamide, carboplatin, and etoposide versus gemcitabine and vinorelbine regimen for pediatric patients with relapsed or refractory Hodgkin’s lymphoma
by: Ahmed Mahdy, et al.
Published: (2023-06-01)

Efficacy and toxicity of gemcitabine/ dexamethasone / carboplatin versus ESHAP protocol in treatment of relapsed/ refractory Non-Hodgkin’s lymphomas (NHL)
by: Fatma Abbas, et al.
Published: (2022-04-01)

PB2308: NIVOLUMAB-BASED THERAPY OF RELAPSED OR REFRACTORY PRIMARY LARGE B-CELL LYMPHOMA OF IMMUNE-PRIVILEGED SITES AND DLBCL WITH SECONDARY CNS INVOLVEMENT
by: Andrey Gavrilenko, et al.
Published: (2023-08-01)

P1138: FIVE-YEAR EFFICACY AND SAFETY OF TAFASITAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY DLBCL: FINAL RESULTS FROM THE PHASE II L-MIND STUDY
by: Johannes Duell, et al.
Published: (2023-08-01)

1174 Costimulatory IgM T-cell engagers with enhanced and durable cytotoxicity
by: Yue Wang, et al.
Published: (2023-11-01)

SG-APSIC1174: High-value instrument management: Rigid endoscopes
by: Nanthipha Sirijindadirat
Published: (2023-02-01)

PB2119: LONG-TERM SURVIVAL PROJECTIONS OF LONCASTUXIMAB TESIRINE-TREATED PATIENTS IN RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
by: M. Hamadani, et al.
Published: (2022-06-01)

P1134: BISPECIFIC ANTI-CD20/19 CAR-T – ZAMTOCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY DLBCL – INTERIM ANALYSIS RESULTS OF DALY-II-USA STUDY
by: Nirav Shah, et al.
Published: (2023-08-01)

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
by: Cinzia Pellegrini, et al.
Published: (2016-04-01)

The Immunology of DLBCL
by: Taishi Takahara, et al.
Published: (2023-01-01)

P1144: PHASE 2 WAVELINE-004 STUDY: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
by: Muhit Ozcan, et al.
Published: (2023-08-01)

P1152: DEPTH OF METABOLIC RESPONSE AT INTERIM PET AND SURVIVAL OUTCOMES AMONG PATIENTS WITH PRIMARY REFRACTORY OR EARLY RELAPSING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
by: Allison Bock, et al.
Published: (2023-08-01)

حکام دمشق والحروب الصلیبیة 491-570هـ / 1098- 1174م
by: راغب البکر
Published: (1995-09-01)

Exceptional Responder to Immunotherapy: A Rare Case of Post- HSCT DLBCL Relapse Responding to Nivolumab
by: Irappa Madabhavi, et al.
Published: (2019-04-01)

CD19-Directed CAR T Cells Treatment in a Patient with Refractory DLBCL and CNS Involvement
by: Antonia Maria S. Müller, et al.
Published: (2019-09-01)

The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 studyResearch in context
by: Radhakrishnan Ramchandren, et al.
Published: (2023-02-01)

DLBCL Coast to Coast
by: Melania Tesio
Published: (2018-02-01)

Significance of bulky mass and residual tumor—Treated with or without consolidative radiotherapy—To the risk of relapse in DLBCL patients
by: Susanna Tokola, et al.
Published: (2020-03-01)

T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma
by: Alison J. Moskowitz, et al.
Published: (2022-10-01)

P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY
by: N. L. Bartlett, et al.
Published: (2022-06-01)

The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL – Results From the Phase-II STORM Trial
by: Mathias Witzens-Harig, et al.
Published: (2021-10-01)

Relapsed/Refractory Hodgkin Lymphoma
by: Semira Sheikh, et al.
Published: (2018-06-01)